Copyright Reports & Markets. All rights reserved.

Global Epidermolysis Bullosa Therapeutics Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Epidermolysis Bullosa Therapeutics

      • 1.1 Definition of Epidermolysis Bullosa Therapeutics
      • 1.2 Epidermolysis Bullosa Therapeutics Segment by Type
        • 1.2.1 Global Epidermolysis Bullosa Therapeutics Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 EB-201
        • 1.2.3 FCX-007
        • 1.2.4 ICX-RHY
        • 1.2.5 INM-750
        • 1.2.6 Others
      • 1.3 Epidermolysis Bullosa Therapeutics Segment by Applications
        • 1.3.1 Global Epidermolysis Bullosa Therapeutics Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Clinic
        • 1.3.3 Hospital
        • 1.3.4 Others
      • 1.4 Global Epidermolysis Bullosa Therapeutics Overall Market
        • 1.4.1 Global Epidermolysis Bullosa Therapeutics Revenue (2014-2025)
        • 1.4.2 Global Epidermolysis Bullosa Therapeutics Production (2014-2025)
        • 1.4.3 North America Epidermolysis Bullosa Therapeutics Status and Prospect (2014-2025)
        • 1.4.4 Europe Epidermolysis Bullosa Therapeutics Status and Prospect (2014-2025)
        • 1.4.5 China Epidermolysis Bullosa Therapeutics Status and Prospect (2014-2025)
        • 1.4.6 Japan Epidermolysis Bullosa Therapeutics Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Epidermolysis Bullosa Therapeutics Status and Prospect (2014-2025)
        • 1.4.8 India Epidermolysis Bullosa Therapeutics Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Epidermolysis Bullosa Therapeutics
      • 2.3 Manufacturing Process Analysis of Epidermolysis Bullosa Therapeutics
      • 2.4 Industry Chain Structure of Epidermolysis Bullosa Therapeutics

      3 Development and Manufacturing Plants Analysis of Epidermolysis Bullosa Therapeutics

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Epidermolysis Bullosa Therapeutics Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Epidermolysis Bullosa Therapeutics
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Epidermolysis Bullosa Therapeutics Production and Capacity Analysis
      • 4.2 Epidermolysis Bullosa Therapeutics Revenue Analysis
      • 4.3 Epidermolysis Bullosa Therapeutics Price Analysis
      • 4.4 Market Concentration Degree

      5 Epidermolysis Bullosa Therapeutics Regional Market Analysis

      • 5.1 Epidermolysis Bullosa Therapeutics Production by Regions
        • 5.1.1 Global Epidermolysis Bullosa Therapeutics Production by Regions
        • 5.1.2 Global Epidermolysis Bullosa Therapeutics Revenue by Regions
      • 5.2 Epidermolysis Bullosa Therapeutics Consumption by Regions
      • 5.3 North America Epidermolysis Bullosa Therapeutics Market Analysis
        • 5.3.1 North America Epidermolysis Bullosa Therapeutics Production
        • 5.3.2 North America Epidermolysis Bullosa Therapeutics Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Epidermolysis Bullosa Therapeutics Import and Export
      • 5.4 Europe Epidermolysis Bullosa Therapeutics Market Analysis
        • 5.4.1 Europe Epidermolysis Bullosa Therapeutics Production
        • 5.4.2 Europe Epidermolysis Bullosa Therapeutics Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Epidermolysis Bullosa Therapeutics Import and Export
      • 5.5 China Epidermolysis Bullosa Therapeutics Market Analysis
        • 5.5.1 China Epidermolysis Bullosa Therapeutics Production
        • 5.5.2 China Epidermolysis Bullosa Therapeutics Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Epidermolysis Bullosa Therapeutics Import and Export
      • 5.6 Japan Epidermolysis Bullosa Therapeutics Market Analysis
        • 5.6.1 Japan Epidermolysis Bullosa Therapeutics Production
        • 5.6.2 Japan Epidermolysis Bullosa Therapeutics Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Epidermolysis Bullosa Therapeutics Import and Export
      • 5.7 Southeast Asia Epidermolysis Bullosa Therapeutics Market Analysis
        • 5.7.1 Southeast Asia Epidermolysis Bullosa Therapeutics Production
        • 5.7.2 Southeast Asia Epidermolysis Bullosa Therapeutics Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Epidermolysis Bullosa Therapeutics Import and Export
      • 5.8 India Epidermolysis Bullosa Therapeutics Market Analysis
        • 5.8.1 India Epidermolysis Bullosa Therapeutics Production
        • 5.8.2 India Epidermolysis Bullosa Therapeutics Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Epidermolysis Bullosa Therapeutics Import and Export

      6 Epidermolysis Bullosa Therapeutics Segment Market Analysis (by Type)

      • 6.1 Global Epidermolysis Bullosa Therapeutics Production by Type
      • 6.2 Global Epidermolysis Bullosa Therapeutics Revenue by Type
      • 6.3 Epidermolysis Bullosa Therapeutics Price by Type

      7 Epidermolysis Bullosa Therapeutics Segment Market Analysis (by Application)

      • 7.1 Global Epidermolysis Bullosa Therapeutics Consumption by Application
      • 7.2 Global Epidermolysis Bullosa Therapeutics Consumption Market Share by Application (2014-2019)

      8 Epidermolysis Bullosa Therapeutics Major Manufacturers Analysis

      • 8.1 Birken AG
        • 8.1.1 Birken AG Epidermolysis Bullosa Therapeutics Production Sites and Area Served
        • 8.1.2 Birken AG Product Introduction, Application and Specification
        • 8.1.3 Birken AG Epidermolysis Bullosa Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Fibrocell Science, Inc.
        • 8.2.1 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Production Sites and Area Served
        • 8.2.2 Fibrocell Science, Inc. Product Introduction, Application and Specification
        • 8.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 GlaxoSmithKline Plc
        • 8.3.1 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Production Sites and Area Served
        • 8.3.2 GlaxoSmithKline Plc Product Introduction, Application and Specification
        • 8.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 InMed Pharmaceuticals Inc.
        • 8.4.1 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Production Sites and Area Served
        • 8.4.2 InMed Pharmaceuticals Inc. Product Introduction, Application and Specification
        • 8.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Karus Therapeutics Limited
        • 8.5.1 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Production Sites and Area Served
        • 8.5.2 Karus Therapeutics Limited Product Introduction, Application and Specification
        • 8.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 ProQR Therapeutics N.V.
        • 8.6.1 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Production Sites and Area Served
        • 8.6.2 ProQR Therapeutics N.V. Product Introduction, Application and Specification
        • 8.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 RegeneRx Biopharmaceuticals, Inc.
        • 8.7.1 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Production Sites and Area Served
        • 8.7.2 RegeneRx Biopharmaceuticals, Inc. Product Introduction, Application and Specification
        • 8.7.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Scioderm, Inc.
        • 8.8.1 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Production Sites and Area Served
        • 8.8.2 Scioderm, Inc. Product Introduction, Application and Specification
        • 8.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Stratatech Corporation
        • 8.9.1 Stratatech Corporation Epidermolysis Bullosa Therapeutics Production Sites and Area Served
        • 8.9.2 Stratatech Corporation Product Introduction, Application and Specification
        • 8.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 TWi Pharmaceuticals, Inc.
        • 8.10.1 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Production Sites and Area Served
        • 8.10.2 TWi Pharmaceuticals, Inc. Product Introduction, Application and Specification
        • 8.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served
      • 8.11 WAVE Life Sciences Ltd.

      9 Development Trend of Analysis of Epidermolysis Bullosa Therapeutics Market

      • 9.1 Global Epidermolysis Bullosa Therapeutics Market Trend Analysis
        • 9.1.1 Global Epidermolysis Bullosa Therapeutics Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Epidermolysis Bullosa Therapeutics Regional Market Trend
        • 9.2.1 North America Epidermolysis Bullosa Therapeutics Forecast 2019-2025
        • 9.2.2 Europe Epidermolysis Bullosa Therapeutics Forecast 2019-2025
        • 9.2.3 China Epidermolysis Bullosa Therapeutics Forecast 2019-2025
        • 9.2.4 Japan Epidermolysis Bullosa Therapeutics Forecast 2019-2025
        • 9.2.5 Southeast Asia Epidermolysis Bullosa Therapeutics Forecast 2019-2025
        • 9.2.6 India Epidermolysis Bullosa Therapeutics Forecast 2019-2025
      • 9.3 Epidermolysis Bullosa Therapeutics Market Trend (Product Type)
      • 9.4 Epidermolysis Bullosa Therapeutics Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Epidermolysis Bullosa Therapeutics Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Epidermolysis Bullosa Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Epidermolysis Bullosa Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Epidermolysis Bullosa Therapeutics market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Epidermolysis Bullosa Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Epidermolysis Bullosa Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Birken AG
        Fibrocell Science, Inc.
        GlaxoSmithKline Plc
        InMed Pharmaceuticals Inc.
        Karus Therapeutics Limited
        ProQR Therapeutics N.V.
        RegeneRx Biopharmaceuticals, Inc.
        Scioderm, Inc.
        Stratatech Corporation
        TWi Pharmaceuticals, Inc.
        WAVE Life Sciences Ltd.

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        EB-201
        FCX-007
        ICX-RHY
        INM-750
        Others

        Segment by Application
        Clinic
        Hospital
        Others

        Buy now